X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
oncology (19) 19
index medicus (18) 18
female (15) 15
male (14) 14
middle aged (14) 14
aged (12) 12
lung neoplasms - drug therapy (12) 12
adult (10) 10
chemotherapy (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
carcinoma, non-small-cell lung - drug therapy (9) 9
carboplatin (8) 8
lung neoplasms - pathology (8) 8
treatment outcome (8) 8
lung neoplasms - mortality (7) 7
aged, 80 and over (6) 6
bevacizumab (6) 6
carcinoma, non-small-cell lung - mortality (6) 6
carcinoma, non-small-cell lung - pathology (6) 6
docetaxel (6) 6
paclitaxel (6) 6
respiratory system (6) 6
therapy (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
carboplatin - administration & dosage (5) 5
gemcitabine (5) 5
lung cancer, non-small cell (5) 5
neoplasm staging (5) 5
quality of life (5) 5
survival analysis (5) 5
tumors (5) 5
young adult (5) 5
antineoplastic agents - therapeutic use (4) 4
care and treatment (4) 4
clinical trials (4) 4
gefitinib (4) 4
multicenter (4) 4
non-small cell lung carcinoma (4) 4
paclitaxel - administration & dosage (4) 4
1st-line therapy (3) 3
1st-line treatment (3) 3
abridged index medicus (3) 3
animals (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - adverse effects (3) 3
base sequence (3) 3
biochemistry & molecular biology (3) 3
cancer (3) 3
cancer therapies (3) 3
cell biology (3) 3
cells (3) 3
cisplatin (3) 3
combination (3) 3
dna-binding proteins - metabolism (3) 3
drug administration schedule (3) 3
gene-expression (3) 3
histology (3) 3
intravenous topotecan (3) 3
kaplan-meier estimate (3) 3
lung neoplasms (3) 3
metastasis (3) 3
mice (3) 3
mutation (3) 3
non-small cell lung cancer (3) 3
nsclc (3) 3
open-label (3) 3
osteo-sarcoma virus (3) 3
patients (3) 3
research (3) 3
small cell lung carcinoma - drug therapy (3) 3
taxoids - administration & dosage (3) 3
transcriptional activation (3) 3
trial (3) 3
vascular endothelial growth factor (3) 3
acute myeloid-leukemia (2) 2
adenocarcinoma (2) 2
adolescent (2) 2
adverse outcomes (2) 2
anthracyclines - adverse effects (2) 2
anthracyclines - therapeutic use (2) 2
antibodies, monoclonal (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - pharmacology (2) 2
apoptosis (2) 2
article (2) 2
benzamides - administration & dosage (2) 2
c-fos (2) 2
carcinoma, large cell - pathology (2) 2
carcinoma, non-small-cell lung (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, non-small-cell lung - secondary (2) 2
carcinoma, non-small-cell lung - therapy (2) 2
cell line (2) 2
cell lung-cancer (2) 2
cell transformation, neoplastic (2) 2
cisplatin - administration & dosage (2) 2
clinical-practice guidelines (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 12, pp. 1187 - 1188
To the Editor: In the IMpower150 study, Socinski et al. (June 14 issue) 1 sought to determine whether vascular endothelial growth factor blockade enhances the... 
MEDICINE, GENERAL & INTERNAL | Antibodies, Monoclonal | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Humans | Survival analysis | Chemotherapy | Immunotherapy | Paclitaxel | Carboplatin | Non-small cell lung carcinoma | Vascular endothelial growth factor | Patients | Appendix | Bevacizumab
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 34, pp. 4349 - 4357
Journal Article
The New England journal of medicine, 09/2018, Volume 379, Issue 12, p. 1188
Journal Article
Cancer Medicine, ISSN 2045-7634, 11/2015, Volume 4, Issue 11, pp. 1621 - 1632
Molecularly targeted therapies, directed against the features of a given tumor, have allowed for a personalized approach to the treatment of advanced... 
non‐small‐cell lung cancer | gefitinib | Afatinib | dacomitinib | erlotinib | resistance | Resistance | Non-small-cell lung cancer | Dacomitinib | Erlotinib | Gefitinib | CARBOPLATIN-PACLITAXEL | GENE-MUTATIONS | 1ST-LINE TREATMENT | ACQUIRED-RESISTANCE | ASIAN PATIENTS | OPEN-LABEL | EGFR MUTATIONS | TYROSINE KINASE INHIBITORS | ONCOLOGY | RANDOMIZED PHASE-II | NEVER-SMOKERS | non-small-cell lung cancer | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Multigene Family | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | ErbB Receptors - genetics | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Clinical Trials, Phase III as Topic | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - pharmacology | Precision Medicine | Lung Neoplasms - genetics | ErbB Receptors - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Drug Resistance, Neoplasm - genetics | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Care and treatment | Epidermal growth factor | Lung cancer, Non-small cell | Antineoplastic agents | Health aspects | Cancer | Tyrosine | Epidermal growth factor receptors | ErbB protein | Leukemia | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Histology | Metastasis | FDA approval | Kinases | Cancer therapies | Ethnicity | Chemotherapy | Clinical medicine | Protein-tyrosine kinase | Tumors | Clinical Cancer Research
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 09/2019, Volume 14, Issue 9, pp. 1628 - 1639
Introduction: CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria... 
ECOG PS | TRIALS | ONCOLOGY | RESPIRATORY SYSTEM | Nivolumab | Non-small cell lung cancer | Safety | Elderly | DOCETAXEL
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. TPS9103 - TPS9103
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2015, Volume 33, Issue 1, pp. 148 - 158
Background This phase Ib study used a parallel, multi-arm design to examine tasisulam-sodium (hereafter tasisulam), a drug with complex pharmacology, combined... 
Phase Ib | Medicine & Public Health | Erlotinib | LY573636 | Docetaxel | Tasisulam | Oncology | Temozolomide | Pharmacology/Toxicology | Dose-escalation | Gemcitabine HCl | Cisplatin | RANDOMIZED-TRIAL | GEMCITABINE | CHEMOTHERAPY | CELL LUNG-CANCER | ONCOLOGY | 3RD-LINE TREATMENT | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | SODIUM LY573636 SODIUM | 1ST-LINE THERAPY | SOFT-TISSUE SARCOMA | Erlotinib Hydrochloride | Neoplasms - metabolism | Dacarbazine - adverse effects | Benzamides - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Young Adult | Sulfonamides - blood | Benzamides - administration & dosage | Dacarbazine - analogs & derivatives | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Benzamides - adverse effects | Taxoids - adverse effects | Dacarbazine - administration & dosage | Benzamides - blood | Deoxycytidine - administration & dosage | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Taxoids - administration & dosage | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Cisplatin - adverse effects | Sulfonamides - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Antineoplastic agents | Drug therapy | Tumors | Studies | Clinical trials | Chemotherapy | Pharmaceutical sciences | Index Medicus
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.